Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors

Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Study ID
NCT00005061
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory solid tumors.

Key Dates

First listed
Apr 12, 2004
Start date
Dec 31, 1999
Status verified
Jul 2012
Primary completion
Jun 30, 2001

Study Design

Enrollment
20 participants (actual)
Primary purpose
TREATMENT

Related Studies